Drug intelligence / Profile preview

ABD-006

Development stage: Preclinical
Lead developer: Abdera Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ABD-006 is a radiolabeled antibody therapeutic candidate being developed as a precision radiopharmaceutical for the treatment of neoplasms (cancers). It is designed to deliver targeted radiation to tumor cells by binding to an undisclosed solid tumor antigen, leveraging Abdera Therapeutics' proprietary ROVEr platform. The drug is currently in preclinical development and has not yet entered clinical trials. Its mechanism of action involves the use of an antibody conjugated with a radioactive isotope, enabling selective delivery of cytotoxic radiation to cancer cells while sparing healthy tissue. The primary indication under investigation is neoplasms.

Beyond the preview

Go deeper on ABD-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABD-006.

Explore the full profile